NORTHROP GRUMMAN CORP

Northrop Grumman’s $580 price target drop reflects margin‑compression risks amid defense spending shifts, offering investors insight into potential upside and valuation pressure.

Northrop Grumman secures a 5‑year U.S. Army contract for M1147 tank ammunition, boosting revenue, reinforcing supply‑chain resilience, and solidifying its defense leadership.

Northrop Grumman’s upgraded outlook: S&P lifts rating as defense demand surges, with strong ISR growth, drone market gains and a $435 fair‑value estimate—why the stock could keep climbing.

Northrop Grumman’s Q1 beats estimates but shares dip—backlog of $96 bn, B‑21 stealth bomber, and rising defense spend suggest 29 % upside and solid long‑term earnings growth.

Northrop Grumman’s MBDA partnership and maritime safety push signal strong 2025‑2032 upside, with analysts eyeing a $710 target amid growing defense demand.